Cutaneous toxicities of new treatments for melanoma

A. Boada, C. Carrera, S. Segura, H. Collgros, P. Pasquali, D. Bodet, S. Puig, J. Malvehy

    Research output: Contribution to journalReview articleResearchpeer-review

    21 Citations (Scopus)


    © 2018, Federación de Sociedades Españolas de Oncología (FESEO). New drugs against advanced melanoma have emerged during last decade. Target therapy and immunotherapy have changed the management of patients with metastatic disease. Along with its generalized use, drug toxicities have appeared and the skin is the target organ of a significant part of them. This revision summarizes the most common side effects and consensus management to improve the compliance of therapies and patients’ quality of life. Among the BRAF inhibitors, main cutaneous side effects are photosensitivity, plantar hyperkeratosis, and the appearance of verrucal keratosis or squamous cell carcinoma. Special attention must be paid to the development of new primary melanomas or changes on nevi during BRAF inhibitor therapy. The most common cutaneous side effects of immunotherapy are rash, pruritus, and vitiligo. It remains controversial the possible role of these toxicities as markers of response to therapy.
    Original languageEnglish
    Pages (from-to)1373-1384
    JournalClinical and Translational Oncology
    Issue number11
    Publication statusPublished - 1 Nov 2018


    • Immunotherapy
    • Melanoma
    • Nivolumab
    • Pembrolizumab
    • Target therapy
    • Toxicity


    Dive into the research topics of 'Cutaneous toxicities of new treatments for melanoma'. Together they form a unique fingerprint.

    Cite this